A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study

Trial Profile

A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs BL 8040 (Primary) ; Pembrolizumab (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms COMBAT
  • Sponsors BioLineRx
  • Most Recent Events

    • 21 Nov 2017 According to a BioLineRx media release, partial results from the monotherapy portion from this trial will be presented at the ASCO GI conference and abstract for this presentation will be published prior to the conference in January 2018.
    • 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2017 Top line results from this trial are expected in H2 2018 according to a BioLineRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top